Jingjing Yan

Jingjing(JJ) Yan is the Founder of Probe Capital, an investment bank specializing in healthcare and deep tech. Through capital allocation, he supports Chinese technology companies in addressing challenges of global relevance. Since founding Probe Capital, he has helped more than 200 companies raise over RMB 30 billion in financing, spanning innovative drugs, medical devices, AI healthcare, advanced manufacturing and new energy. Within the framework of Human Development, healthcare is where Yan’s work matters most. The innovative drug, medical device and AI healthcare companies he serves are, in essence, all answering the same question — how to help more people live longer, better lives. Aging, chronic disease and cancer are shared global challenges, and China’s healthcare innovation is delivering accessible, affordable solutions to them. He believes the role of capital goes beyond closing deals: it is to direct resources toward technological innovation that solves real problems — turning progress into human well-being, and turning Chinese companies’ local practice into global value.

严晶晶，探针资本（Probe Capital）创始人，长期专注医疗与硬科技领域的产业投行与投资，以资本配置支持中国科技企业解决具有全球相关性的人类问题。创办至今，已帮助 200 余家企业完成超 300 亿元规模的融资，覆盖创新药、医疗器械、AI 医疗、先进制造与新能源等赛道。 在“人类发展”维度下，医疗健康是严晶晶最关注的落点。他服务的创新药、医疗器械与 AI 医疗企业，本质上都在回答同一个问题——如何让更多人活得更久、活得更好。老龄化、慢病与肿瘤是全球共同挑战，中国的医疗创新正在为其提供可及、可负担的解决方案。 他自研了专注于气候与碳领域的AI 投资辅助工具 Sano Claw。 他相信，资本不只是促成交易，而是把资源引导到“解决真实问题”的科技创新上，让技术进步转化为人的福祉，也让中国企业的本土实践，转化为超越中国市场的全球价值。